Combination of MIR-103a-3p and mesothelin improves the biomarker performance of malignant mesothelioma diagnosis

PLoS ONE

Volumn 9, Issue 12, 2014, Pages

  Weber, Daniel G ^a   Casjens, Swaantje ^a   Johnen, Georg ^a   Bryk, Oleksandr ^a   Raiko, Irina ^a   Pesch, Beate ^a   Kollmeier, Jens ^b   Bauer, Torsten T ^b   Brüning, Thomas ^a  

^a RUHR UNIVERSITY BOCHUM   (Germany)

^b Helios Klinkum Emil von Behring   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ASBESTOS; MESOTHELIN; MICRORNA; MICRORNA 103A-3P; UNCLASSIFIED DRUG; GLYCOSYLPHOSPHATIDYLINOSITOL ANCHORED PROTEIN; MIRN103 MICRORNA, HUMAN; TUMOR MARKER;

ADULT; AGED; ARTICLE; BIPHASIC MESOTHELIOMA; CLINICAL ARTICLE; CONTROLLED STUDY; DIAGNOSTIC VALUE; EPITHELIOID MESOTHELIOMA; FALSE NEGATIVE RESULT; FALSE POSITIVE RESULT; HUMAN; MALE; MALIGNANT MESOTHELIOMA; PLASMA; RECEIVER OPERATING CHARACTERISTIC; SARCOMATOID MESOTHELIOMA; SENSITIVITY AND SPECIFICITY; BLOOD; LUNG NEOPLASMS; MESOTHELIOMA; MIDDLE AGED; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; BIOMARKERS, TUMOR; GPI-LINKED PROTEINS; HUMANS; LUNG NEOPLASMS; MALE; MESOTHELIOMA; MICRORNAS; MIDDLE AGED; ROC CURVE;

EID: 84936814469     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0114483     Document Type: Article

References (37)

1. Robinson BM (2012) Malignant pleural mesothelioma: An epidemiological perspective. Ann Cardiothorac Surg 1: 491-496.
2. Price B, Ware A (2004) Mesothelioma trends in the United States: An update based on Surveillance, Epidemiology, and End Results Program data for 1973 through 2003. Am J Epidemiol 159: 107-112.
3. Hodgson JT, McElvenny DM, Darnton AJ, Price MJ, Peto J (2005) The expected burden of mesothelioma mortality in Great Britain from 2002 to 2050. Br J Cancer 92: 587-593.
4. Myojin T, Azuma K, Okumura J, Uchiyama I (2012) Future trends of mesothelioma mortality in Japan based on a risk function. Ind Health 50: 197-204.
5. Vogelzang NJ, Rusthoven JJ, Symanowski J, Denham C, Kaukel E, et al. (2003) Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. J Clin Oncol 21: 2636-2644.
6. Yoneda K, Tanaka F, Kondo N, Hashimoto M, Takuwa T, et al. (2013) Circulating Tumor Cells (CTCs) in Malignant Pleural Mesothelioma (MPM). Ann Surg Oncol. In press.
7. Jakubec P, Pelclova D, Smolkova P, Kolek V, Nakladalova M (2014) Significance of serum mesothelin in an asbestos-exposed population in the Czech Republic. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. In press.
8. Pesch B, Bruning T, Johnen G, Casjens S, Bonberg N, et al. (2014) Biomarker research with prospective study designs for the early detection of cancer. Biochim Biophys Acta 1844: 874-883.
9. Beyer HL, Geschwindt RD, Glover CL, Tran L, Hellstrom I, et al. (2007) MESOMARK: A potential test for malignant pleural mesothelioma. Clinical Chemistry 53: 666-672.
10. Raiko I, Sander I, Weber DG, Raulf-Heimsoth M, Gillissen A, et al. (2010) Development of an enzyme-linked immunosorbent assay for the detection of human calretinin in plasma and serum of mesothelioma patients. BMC Cancer 10: 242.
11. Pass HI, Levin SM, Harbut MR, Melamed J, Chiriboga L, et al. (2012) Fibulin-3 as a blood and effusion biomarker for pleural mesothelioma. The New England journal of medicine 367: 1417-1427.
12. Santarelli L, Strafella E, Staffolani S, Amati M, Emanuelli M, et al. (2011) Association of MiR-126 with Soluble Mesothelin-Related Peptides, a Marker for Malignant Mesothelioma. Plos One 6: e18232.
13. Kirschner MB, Cheng YY, Badrian B, Kao SC, Creaney J, et al. (2012) Increased circulating miR-625- 3p: A potential biomarker for patients with malignant pleural mesothelioma. J Thorac Oncol 7: 1184- 1191.
14. Weber DG, Johnen G, Bryk O, Jö ckel KH, Brü ning T (2012) Identification of miRNA-103 in the Cellular Fraction of Human Peripheral Blood as a Potential Biomarker for Malignant Mesothelioma - A Pilot Study. Plos One 7: e30221.
15. Cui A, Jin XG, Zhai K, Tong ZH, Shi HZ (2014) Diagnostic values of soluble mesothelin-related peptides for malignant pleural mesothelioma: updated meta-analysis. BMJ Open 4: e004145.
16. Weber DG, Taeger D, Pesch B, Kraus T, Bruning T, et al. (2007) Soluble mesothelin-related peptides (SMRP) - High stability of a potential tumor marker for mesothelioma. Cancer biomarkers: section A of Disease markers 3: 287-292.
17. Chen C, Ridzon DA, Broomer AJ, Zhou Z, Lee DH, et al. (2005) Real-time quantification of microRNAs by stem-loop RT-PCR. Nucleic Acids Res 33: e179.
18. Weber DG, Casjens S, Rozynek P, Lehnert M, Zilch-Schö neweis S, et al. (2010) Assessment of mRNA and microRNA Stabilization in Peripheral Human Blood for Multicenter Studies and Biobanks. Biomark Insights 5: 95-102.
19. Creaney J, van Bruggen I, Hof M, Segal A, Musk AW, et al. (2007) Combined CA125 and Mesothelin Levels for the Diagnosis of Malignant Mesothelioma. Chest 132: 1239-1246.
20. Gube M, Taeger D, Weber DG, Pesch B, Brand P, et al. (2011) Performance of biomarkers SMRP, CA125, and CYFRA 21-1 as potential tumor markers for malignant mesothelioma and lung cancer in a cohort of workers formerly exposed to asbestos. Arch Toxicol 85: 185-192.
21. Corradi M, Goldoni M, Alinovi R, Tiseo M, Ampollini L, et al. (2013) YKL-40 and Mesothelin in the Blood of Patients with Malignant Mesothelioma, Lung Cancer and Asbestosis. Anticancer Res 33: 5517- 5524.
22. Cristaudo A, Bonotti A, Simonini S, Vivaldi A, Guglielmi G, et al. (2011) Combined serum mesothelin and plasma osteopontin measurements in malignant pleural mesothelioma. J Thorac Oncol 6: 1587- 1593.
23. Muley T, Dienemann H, Herth FJ, Thomas M, Meister M, et al. (2013) Combination of mesothelin and CEA significantly improves the differentiation between malignant pleural mesothelioma, benign asbestos disease, and lung cancer. J Thorac Oncol 8: 947-951.
24. Tang Z, Qian M, Ho M (2013) The role of mesothelin in tumor progression and targeted therapy. Anticancer Agents Med Chem 13: 276-280.
25. Zhou H, Rigoutsos I (2014) MiR-103a-3p targets the 59 UTR of GPRC5A in pancreatic cells. RNA 20: 1431-1439.
26. Acquafreda T, Soprano KJ, Soprano DR (2009) GPRC5A: A potential tumor suppressor and oncogene. Cancer Biol Ther 8: 963-965.
27. Ordonez NG, Sahin AA (2014) Diagnostic utility of immunohistochemistry in distinguishing between epithelioid pleural mesotheliomas and breast carcinomas: A comparative study. Hum Pathol 45: 1529- 1540.
28. Shen S, Sun Q, Liang Z, Cui X, Ren X, et al. (2014) A prognostic model of triple-negative breast cancer based on miR-27b-3p and node status. PLoS One 9: e100664.
29. Liu X, He M, Hou Y, Liang B, Zhao L, et al. (2013) Expression profiles of microRNAs and their target genes in papillary thyroid carcinoma. Oncology reports 29: 1415-1420.
30. Tan KS, Armugam A, Sepramaniam S, Lim KY, Setyowati KD, et al. (2009) Expression profile of MicroRNAs in young stroke patients. PLoS One 4: e7689.
31. Grigoriu BD, Grigoriu C, Chahine B, Gey T, Scherpereel A (2009) Clinical utility of diagnostic markers for malignant pleural mesothelioma. Monaldi Arch Chest Dis 71: 31-38.
32. Henderson DW, Reid G, Kao SC, van Zandwijk N, Klebe S (2013) Challenges and controversies in the diagnosis of malignant mesothelioma: Part 2. Malignant mesothelioma subtypes, pleural synovial sarcoma, molecular and prognostic aspects of mesothelioma, BAP1, aquaporin-1 and microRNA. J Clin Pathol 66: 854-861.
33. Fraser CG (2004) Inherent biological variation and reference values. Clin Chem Lab Med 42: 758-764.
34. Kirschner MB, Edelman JJ, Kao SC, Vallely MP, van Zandwijk N, et al. (2013) The Impact of Hemolysis on Cell-Free microRNA Biomarkers. Front Genet 4: 94.
35. Lowe KA, Shah C, Wallace E, Anderson G, Paley P, et al. (2008) Effects of personal characteristics on serum CA125, mesothelin, and HE4 levels in healthy postmenopausal women at high-risk for ovarian cancer. Cancer Epidemiol Biomarkers Prev 17: 2480-2487.
36. Di Serio F, Fontana A, Loizzi M, Capotorto G, Maggiolini P, et al. (2007) Mesothelin family proteins and diagnosis of mesothelioma: Analytical evaluation of an automated immunoassay and preliminary clinical results. Clin Chem Lab Med 45: 634-638.
37. Tsongalis GJ, Calin G, Cordelier P, Croce C, Monzon F, et al. (2013) MicroRNA analysis: is it ready for prime time? Clinical Chemistry 59: 343-347.